If you have looked for standalone TB-500 at telos rx and not found it, there is a specific, honest reason. It is worth understanding rather than guessing at.
telos rx currently offers TB-500 only within the BPC-157 + TB-500 stack. TB-500 sat in FDA's Category 2 from late 2023 until April 22, 2026, and on October 28, 2026 HHS announced a temporary policy that covers TB-500 only as a single-ingredient compounded product, under strict conditions. It is not FDA approval.
See the BPC-157 + TB-500 stack →The direct answer
telos rx currently offers TB-500 only within the BPC-157 + TB-500 stack. When this article was first written, the reason given was regulatory: from late 2023 until April 22, 2026, FDA listed TB-500 in Category 2, a group of bulk substances it had flagged over safety questions, which kept compounding pharmacies from preparing it.
That picture has changed. In July 2026 an FDA advisory committee voted to recommend adding TB-500 to the list of substances that can be used in compounding. Then, on October 28, 2026, HHS announced an interim enforcement discretion policy covering TB-500 and five other peptides. Under it, HHS does not intend to take enforcement action against state-licensed pharmacies or licensed physicians that compound TB-500 with a valid prescription, as long as strict conditions are met, including FDA-registered suppliers, lot-level testing, subcutaneous or intramuscular use only, and single-ingredient products. It is temporary while FDA decides through rulemaking, it is not FDA approval, and HHS can revisit it if safety or quality problems arise.
What Category 2 meant, and what replaced it
Compounding pharmacies operate within a framework that sorts bulk drug substances into categories, based on the FDA's assessment of available safety information. Category 2 held substances the agency had flagged over safety questions, pending further review. TB-500 was removed from that category on April 22, 2026.
telos rx works only with partner compounding pharmacies that stay within current regulatory guidance. Today that guidance includes the conditions of the HHS policy, one of which is that each compounded product contains a single active ingredient.
What is different about the combination protocol
telos rx does offer a BPC-157 plus TB-500 combination protocol, available through the BPC-157 + TB-500 combination page. It is a separate product from standalone TB-500, and a licensed provider decides whether it fits your history.
One point is worth knowing. The HHS policy applies to TB-500 only as a single-ingredient compounded product. It does not cover blends that combine several peptides in one product, so the policy should not be read as covering every TB-500 combination. The telos rx stack is supplied as two separate vials, one of BPC-157 and one of TB-500, so neither vial is a blend.
What this is not
This is not a claim that TB-500 has been proven unsafe, and it is not telos rx's independent judgment about the peptide. The Category 2 listing described here was a regulatory classification that applied broadly, not a finding by telos rx.
It is also not a signal that the status is settled. The HHS policy is interim and lasts until FDA issues a final rule on TB-500, and telos rx does not claim to know how that rulemaking will end.
Why this kind of restriction exists at all
Compounding regulation exists to give patients some assurance that a prepared medication meets baseline standards. Compounded products are not individually FDA-approved the way manufactured drugs are. Category classifications are one tool the FDA uses to manage that oversight across many nominated substances at once.
Without some system of review, compounding pharmacies would have far less guidance about which bulk substances raise open safety questions. The categories are imperfect, and they change as new information becomes available, but they exist to give both pharmacies and patients a consistent reference point.
Understanding this larger purpose explains why TB-500's status has moved in steps, from Category 2, to an advisory vote, to a temporary HHS policy, rather than changing all at once.
What to do if standalone TB-500 was specifically what you wanted
If your interest was in TB-500 by itself, rather than the combination, it is worth being direct with yourself about that. The combination protocol is a different product. It should be considered on its own merits with a licensed provider, rather than as a workaround.
If you are open to exploring what is actually available, a conversation with a telos rx provider about the BPC-157 plus TB-500 combination or about standalone BPC-157 is a reasonable next step.
How telos rx decides which peptides to offer
telos rx's compounded peptide program is built around what partner compounding pharmacies can legally and safely prepare at a given time. That means the list of available products changes as regulatory guidance changes, not on a fixed schedule set by telos rx alone.
This is different from a typical retail catalog, where a product is simply added when demand justifies it. Availability here is gated first by regulatory status, then by clinical review, and only then by patient demand. For TB-500, the regulatory picture changed in 2026, and telos rx currently offers it only within the BPC-157 + TB-500 stack.
Other peptides discussed in research and recovery communities have their own status. The HHS policy names only six peptides (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500), and others such as GHK-Cu, Selank and ipamorelin are not covered by it.
What patients can reasonably expect going forward
telos rx updates its product pages when a substance's status or its own offering changes, rather than leaving outdated information live. If telos rx adds standalone TB-500, that would be reflected on the relevant pages directly.
Until then, patients researching TB-500 have an accurate, current answer rather than a vague one. Standalone TB-500 is not offered. The BPC-157 plus TB-500 combination protocol is. That is the honest state of things today, and it is worth building any decision around that fact rather than around speculation.
Why honesty matters more than a quick sale
Some marketing pages online blur the line between what a peptide is studied for and what is actually available to order. A confident-sounding page tends to convert better than an honest one. telos rx takes a different approach in this wave of educational content.
Stating plainly that a substance is not currently offered, and explaining the actual regulatory reason, costs a potential sale in the short term. It also means a patient reading this article can trust what it says, rather than wondering whether the page is quietly overselling something that is not really there.
That same standard applies to the BPC-157 plus TB-500 combination protocol. It is described as what it is, a distinct, reviewed protocol, not as standalone TB-500 with a different label attached to it.
A brief note on how to weigh secondhand information
Recovery and research communities online are a mix of genuinely informed contributors and confident-sounding guesswork. Both can look similar at a glance, especially in a forum thread or a comment section without named sources.
When you read a claim about TB-500's availability, ask where it comes from and how recent it is. A claim tied to a specific, checkable fact, like a named FDA classification and a date, is easier to verify than a vague assertion that a peptide is easy to get somewhere.
This article ties its claims to specific, dated documents you can look up yourself, including the Federal Register notice for the HHS policy, rather than asking you to simply trust the source. That is a habit worth applying to any health-related claim you encounter online, whether it involves TB-500 or an entirely different substance.
A licensed provider is also a resource here. If you read something online about TB-500 that this article does not address, raising it during an intake conversation is a reasonable way to get a direct, individualized answer.
Where to read more, from primary sources
For general background on how the FDA approaches compounding oversight, see the FDA's compounding questions and answers page. For published research involving thymosin beta-4, the natural protein TB-500 is derived from, see this PubMed search of the current literature. Reading primary sources directly is a better habit than relying on secondhand summaries, especially for a peptide whose regulatory status and research base are both still evolving.
Frequently Asked Questions
Is telos rx choosing not to sell TB-500, or is it restricted?
When this article was first written, the answer was regulatory: TB-500 sat in FDA's Category 2 from late 2023 until April 22, 2026. On October 28, 2026, HHS announced a temporary enforcement discretion policy that covers TB-500 as a single-ingredient compounded product under strict conditions. It is not FDA approval. telos rx currently offers TB-500 only within the BPC-157 + TB-500 stack.
Do compounding pharmacies have to meet the HHS conditions?
Yes. The HHS policy only applies when every condition is met, including FDA-registered suppliers, lot-level testing, single-ingredient products, permitted routes, adverse event reporting and a valid prescription. telos rx works only with partner pharmacies that stay within current regulatory guidance, which is part of how telos rx maintains its LegitScript certification and patient trust.
Can I still get TB-500 through the combination protocol?
Yes, as part of the BPC-157 plus TB-500 stack, after a licensed provider reviews your intake. telos rx does not currently offer standalone TB-500.
Does this mean TB-500 is dangerous?
No conclusion about safety follows from its regulatory history. TB-500 sat in Category 2 until April 22, 2026, and is now covered by a temporary HHS policy that HHS can revisit if safety or quality problems arise. Human evidence for TB-500 remains limited, and it is not FDA-approved.
Will telos rx offer standalone TB-500 eventually?
There is no confirmed timeline. telos rx describes its current status accurately rather than speculating about future changes, and will update its pages promptly if the status ever changes.
What should I ask my provider if I am interested in this peptide?
Ask specifically about the BPC-157 plus TB-500 combination protocol and whether it fits your goals and history. That is the product currently available, and a provider can walk through it with you in detail, including how it differs from standalone TB-500.
telos rx is LegitScript-certified. Compounded medication is not FDA-approved and is prepared under federal compounding regulations by partner compounding pharmacies. This article is general information, not medical advice, and does not replace guidance from your own provider. Approval is subject to evaluation by a licensed provider, and approval is not guaranteed. Individual results vary. telos rx operates as an online-first, asynchronous telehealth service.
Questions about the BPC-157 + TB-500 combination protocol? Read more and start an online intake on the BPC-157 + TB-500 stack page.